AV Schwartz - Diabetes Care, 2008 - hindawi.com Page 1. Hindawi Publishing Corporation PPAR Research Volume 2008, Article ID
297893, 6 pages doi:10.1155/2008/297893 Review Article TZDs and Bone: A Review
of the Recent Clinical Evidence Ann V. Schwartz Department ... Cited by 9 - Related articles - View as HTML - All 11 versions
CV Rizos, M Elisaf, DP Mikhailidis, EN … - Expert Opin. Drug …, 2009 - informahealthcare.com Background: Thiazolidinediones (TZDs) are widely used antidiabetic drugs with proven efficacy
regarding mainly surrogate markers of diabetes management. However, efficacy on surrogate
markers may not always translate into benefits in clinical outcomes. Thiazolidinediones ... Cited by 5 - Related articles - All 5 versions
J Dormandy, M Bhattacharya, ART de Bruyn - Drug Safety, 2009 - ingentaconnect.com Abstract People with type 2 diabetes mellitus have an excess risk of macrovascular disease and
a poorer prognosis. PROactive (PROspective pioglitAzone Clinical Trial In macroVascular
Events) was a landmark study of secondary cardiovascular disease (CVD) prevention in ... Cited by 4 - Related articles - All 4 versions
SL Norris, S Carson, C Roberts - Update, 2008 - derp.ohsu.edu The purpose of this report is to make available information regarding the comparative effectiveness
and safety profiles of different drugs within pharmaceutical classes. Reports are not usage
guidelines, nor should they be read as an endorsement of, or recommendation for, any ... Cited by 3 - Related articles - View as HTML - All 8 versions
KR Shockley, OP Lazarenko, PJ Czernik, … - Journal of cellular …, 2009 - pubmedcentral.nih.gov Rosiglitazone (Rosi), a member of the thiazolidinedione class of drugs used to treat type 2
diabetes, activates the adipocyte-specific transcription factor peroxisome proliferator-activated
receptor gamma (PPARγ). This activation causes bone loss in animals and humans, at ... Cited by 3 - Related articles - All 7 versions
M Kellerer - Der Diabetologe, 2009 - Springer Immer mehr Menschen erkranken an Typ-2-Diabetes. Durch die Identifikati- on unterschiedlicher
biochemischer Ri- sikofaktoren und die Analyse von Diabe- tesgenen wird versucht, ein besseres
Ver- ständnis für die Krankheitsentstehung zu gewinnen. Die genetische Charakterisie- ... Cited by 2 - Related articles
- ►nursing2008.com M Bodmer, C Meier, ME Kraenzlin, CR Meier - Drug Safety, 2009 - ingentaconnect.com Michael Bodmer, 1 Christian Meier, 2 Marius E. Kraenzlin 2 and Christoph R. Meier 1,3 ... 1 Basel
Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital
Basel, Basel, Switzerland 2 Division of Endocrinology, Diabetes and Clinical Nutrition, ... Cited by 2 - Related articles - All 6 versions
M Perreault, DV Erbe, JF Tobin - PPAR research, 2008 - hindawi.com Page 1. Hindawi Publishing Corporation PPAR Research Volume 2008, Article ID 125387,
9 pages doi:10.1155/2008/125387 Review Article PPARδ Agonism for the Treatment of
Obesity and Associated Disorders: Challenges and Opportunities ... Cited by 1 - Related articles - View as HTML - All 9 versions
M Carruthers, TR Trinick, E Jankowska, AM … - Cardiovascular …, 2008 - cardiab.com The literature on the clinical, metabolic and endocrine effects of glitazones in relation to the reported
actions of testosterone in diabetes, metabolic syndrome, and cardiovascular disease is
reviewed, and the following unifying hypothesis advanced: "Glitazones induce androgen ... Cited by 1 - Related articles - Cached - All 8 versions
